Brazil mandates specific asthma and cancer drug coverage for supplemental health plans
Supplemental health plans in Brazil must now cover specific asthma and cancer drugs. The National Agency for Supplementary Health (ANS) recently approved mandatory coverage for one asthma medication and three cancer drugs (as written in the Normative Resolution 550 published in the Diário Ofcialda União (DOU). According to SCIATH, Asinta’s employee benefits consulting Partner in the country, the medications and their uses are as follows:
Dupilumab is an immunobiological drug used to treat severe asthma with type 2 inflammation with an allergic phenotype.
Niraparib is used in maintenance therapies for adult patients with advanced, primary high-grade ovarian, fallopian tube, or peritoneal carcinoma.
Axitinib, in combination with Pembrolizumab, is used for the treatment of metastatic or advanced clear cell renal cell carcinoma (RCC) with intermediate or unfavorable prognostic risk in first-line therapy.
Cabozantinib Levomalate, in combination with Nivolumab, is used in the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
SCIATH, Asinta’s employee benefits consulting partner in Brazil, provided this article about Brazil mandating specific asthma and cancer drug coverage. Please contact Asinta if you wish to connect with SCIATH.